Home > Oncology > ASCO 2021 > Genitourinary Cancers > Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma

Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma

Presented By
Dr Arjun Balar , Perlmutter Cancer Center, NY, USA
Conference
ASCO 2021
Trial
Phase 1, INDUCE-1
Results from the phase 1 INDUCE-1 trial showed promising activity and manageable safety of the ICOS agonist feladilimab as monotherapy or combined with pembrolizumab in patients with recurrent/metastatic urothelial carcinoma. Inducible T-cell co-stimulator (ICOS) is a member of the CD23 receptor superfamily, which includes CTLA-4 and PD-1, and has a pivotal role in stimulating T-cell proliferation, differentiation, survival, and function [1]. ICOS is highly expressed in all stages of urothelial cancer. The phase 1 INDUCE trial (NCT02723955) evaluates feladilimab as monotherapy and in combination with pembrolizumab in selected advanced solid tumours. Eligible patients had recurrent/metastatic urothelial carcinoma of the upper or lower urinary tract, 6 or fewer prior systemic therapy lines in the advanced setting, measurable disease, and no active auto...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on